Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+, HER2– Breast Cancer

October 31st 2024

Hope Rugo, MD, FASCO, discusses the FDA approval of inavolisib, how it will be incorporated into care, and the patient population evaluated in INAVO120.

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC

October 31st 2024

The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.

FDA Advises Against Use of BioZorb Markers in Breast Cancer and Other Indications

October 30th 2024

The FDA has announced that BioZorb Markers and BioZorb LP Markers should no longer be used.

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer

October 30th 2024

The FDA has received an NDA seeking the approval of a 3-month formulation of leuprolide mesylate for advanced prostate cancer.

NCCN Guideline Update Recommends Adjuvant Ribociclib Plus AI in HR+/HER2– Early Breast Cancer

October 29th 2024

The October 2024 NCCN Clinical Practice Guidelines in Oncology for breast cancer recommend ribociclib plus an AI in adjuvant HR+/HER2– early breast cancer.

A Multipronged Approach Can Address Disparities in Cancer Care for Patients in Rural Communities

October 27th 2024

Investigators are examining and implementing several innovations that they hope will combat the persistent issue of limited access to cancer care for patients living in rural areas.

Immunotherapy Combinations Dominate Frontline Discussions in Advanced RCC

October 25th 2024

A panel of experts detail updated data and developments in the advanced renal cell carcinoma space with immunotherapy-based combination regimens.

SC Daratumumab Plus VRd Earns EU Approval in Newly Diagnosed, Transplant-Eligible Myeloma

October 23rd 2024

The European Commission has approved daratumumab plus bortezomib, lenalidomide, and dexamethasone in ASCT-eligible, newly diagnosed multiple myeloma.

Fadraciclib Demonstrates Safety, Early Efficacy Signals in CDKN2A/B+ Advanced Solid Tumors

October 23rd 2024

Fadraciclib was safe and showed signs of efficacy in advanced solid tumors harboring CDKN2A/B alterations.

Optimizing Training for Future Clinical Trial Investigators

October 21st 2024

Faculty at Washington University School of Medicine in St. Louis have designed a clinical trial development fellowship education program.

National Fellows Forum Showcases Next Generation of Lung Cancer Clinicians

October 20th 2024

Oncology fellows with aspirations of entering the lung cancer field gathered in Chicago, Illinois, to share findings from their research, network, and participate in panel discussions featuring expert faculty

Diversity Strengthens Fellowship Training and Cancer Care

October 19th 2024

Jerome D. Winegarden, MD, discusses the importance of recruiting international students to such programs.

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

October 15th 2024

Ian Krop, MD, PhD, and Aditya Bardia, MD, MPH, FASCO, detail how TROP2-directed ADCs have generated excitement in breast cancer and other solid tumors.

Treatment Personalization Is Poised to Define New Era of mCRC Therapy

October 11th 2024

A panel of clinicians in the CRC field discussed findings from pivotal clinical trials that were primarily shared during the 2024 ASCO Annual Meeting.

EU Approval Sought for D-VRd in Newly Diagnosed Myeloma

October 10th 2024

A Type II variation application has been submitted to the EMA for subcutaneous daratumumab plus VRd in newly diagnosed multiple myeloma.

Talazoparib Plus Enzalutamide Improves OS in mCRPC

October 10th 2024

The combination of talazoparib and enzalutamide improved overall survival in metastatic castration-resistant prostate cancer.

IMA203 Displays Efficacy in Heavily Pretreated Melanoma

October 10th 2024

IMA203, a TCR-T agent targeting PRAME, was safe and effective in patients with heavily pretreated melanoma.

PARP1-Selective Inhibitors Generate Excitement in Solid Tumors

October 8th 2024

Neeraj Agarwal, MD, FASCO; Andrew J. Armstrong, MD, MSc; and Timothy A. Yap, MBBS, PhD, FRCP, detail the latest research on PARP1-selective inhibitors in oncology.

MAGIC-G1 Study Provides Updated Findings With MTX110 in Recurrent Glioblastoma

October 4th 2024

An update on PFS and OS data from the phase 1 MAGIC-G1 study of MTX110 in recurrent glioblastoma has been released.

FDA Approves Cologuard Plus for Adults at Average Risk for CRC

October 4th 2024

The FDA has approved Cologuard Plus, a next-generation multitarget stool DNA test, for adults at least 45 years of age who are at average risk for CRC.